| Johnson & Johnson31 programs in shared conditions | 15 · 7 with both in phase 3Arthritis, Psoriatic, Carcinoma, Non-Small-Cell Lung, Colitis, Ulcerative +12 | guselkumab, icotrokinra, lazertinib +4 | - AbbVie’s etentamig vs daratumumab (most trials: Johnson & Johnson) (Amyloidosis, NCT07793422)
- Johnson & Johnson’s bleximenib added to venetoclax (US & EU rights: AbbVie) (Leukemia, Myeloid, Acute, NCT06852222)
- AbbVie’s etentamig in a combination vs daratumumab (most trials: Johnson & Johnson) (Multiple Myeloma, NCT07728188)
- and 4 more
|
| Bristol-Myers Squibb26 programs in shared conditions | 13 · 6 with both in phase 3Arthritis, Psoriatic, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms +10 | xanomeline, trospium, trospium chloride +7 | - AbbVie’s turmetabart adizutecan vs amrubicin (most trials: Bristol-Myers Squibb) (Small Cell Lung Carcinoma, NCT07365241)
- AbbVie’s ABBV-1480 added to Albumin-Bound Paclitaxel (EU rights: Bristol-Myers Squibb) (Carcinoma, Non-Small-Cell Lung, NCT07756645)
- AbbVie’s etentamig in a combination vs mezigdomide (most trials: Bristol-Myers Squibb) (Multiple Myeloma, NCT06892522)
- and 1 more
|
| Sanofi10 programs in shared conditions | 7 · 3 with both in phase 3Colitis, Ulcerative, Crohn Disease, Dermatitis, Atopic +4 | duvakitug, Dupilumab coformulated with berahyaluronidase alfa | - AbbVie’s upadacitinib in a combination vs dupilumab (EU rights: Sanofi) (Dermatitis, Atopic, NCT06389136)
- AbbVie’s zumilokibart in a combination vs dupilumab (EU rights: Sanofi) (Dermatitis, Atopic, NCT07027527)
- AbbVie’s APG990 in a combination vs dupilumab (EU rights: Sanofi) (Dermatitis, Atopic, NCT07027527)
|
| Regeneron Pharmaceuticals12 programs in shared conditions | 7 · 1 with both in phase 3Multiple Myeloma, Obesity, Carcinoma, Non-Small-Cell Lung +4 | linvoseltamab, ALN-CIDEB | - AbbVie’s upadacitinib in a combination vs dupilumab (US rights: Regeneron Pharmaceuticals) (Dermatitis, Atopic, NCT06389136)
- AbbVie’s zumilokibart in a combination vs dupilumab (US rights: Regeneron Pharmaceuticals) (Dermatitis, Atopic, NCT07027527)
- AbbVie’s APG990 in a combination vs dupilumab (US rights: Regeneron Pharmaceuticals) (Dermatitis, Atopic, NCT07027527)
|
| Eli Lilly and Company33 programs in shared conditions | 18 · 5 with both in phase 3Carcinoma, Non-Small-Cell Lung, Colitis, Ulcerative, Crohn Disease +15 | donanemab, selpercatinib, olomorasib +7 | - AbbVie’s telisotuzumab adizutecan vs Ramucirumab (US & EU rights: Eli Lilly and Company) (Carcinoma, Non-Small-Cell Lung, NCT07821684)
- Eli Lilly and Company’s lebrikizumab added to Topical Corticosteroid (most trials: AbbVie) (Dermatitis, Atopic, NCT05559359)
- Eli Lilly and Company’s sofetabart mipitecan in a combination vs mirvetuximab soravtansine (US & EU rights: AbbVie) (Fallopian Tube Neoplasms, NCT07213804)
|